Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"VantAI","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VantAI Forms Research Collaboration with Boehringer Ingelheim to Identify Novel Protein Degraders","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2022","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"VantAI","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$674.0 million","upfrontCash":"Undisclosed","newsHeadline":"VantAI Enters Collaboration with Bristol Myers Squibb to Accelerate Molecular Glue Drug Discovery Through Artificial Intelligence","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform"}]

    Find Clinical Drug Pipeline Developments & Deals by VantAI

    Menu

    VantAI

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              VantAI

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              VantAI Enters Collaboration with Bristol Myers Squibb to Accelerate Molecular Glue Drug Discovery Through Artificial Intelligence

              Details:

              The collaboration will focus on leveraging VantAI’s generative AI platform with Bristol Myers Squibb’s expertise in targeted protein degradation to discover and design molecular glues as small molecule therapeutics.

              Lead Product(s): Undisclosed

              Therapeutic Area: Technology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Small molecule

              Partner/Sponsor/Collaborator: Bristol Myers Squibb

              Deal Size: $674.0 million Upfront Cash: Undisclosed

              Deal Type: Collaboration February 13, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              VantAI

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              VantAI Forms Research Collaboration with Boehringer Ingelheim to Identify Novel Protein Degraders

              Details:

              The organizations will leverage VantAI's geometric deep learning platform to computationally streamline the design of new molecules optimized for each E3 platform, leveraging unique target-E3 interface contacts to create innovative routes for important drug parameters.

              Lead Product(s): Undisclosed

              Therapeutic Area: Technology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Small molecule

              Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration April 20, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY